Title |
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
|
---|---|
Published in |
Cochrane database of systematic reviews, July 2013
|
DOI | 10.1002/14651858.cd006910.pub2 |
Pubmed ID | |
Authors |
Theresa A Lawrie, Andrew Bryant, Alison Cameron, Emma Gray, Jo Morrison |
Abstract |
Ovarian cancer is the eighth most common cancer in women and it is usually diagnosed at an advanced stage. The majority of ovarian tumours are epithelial in origin. Women with relapsed epithelial ovarian cancer (EOC) often have a reduced performance status with a limited life expectancy, therefore maintaining quality of life with effective symptom control is the main purpose of treatment. Drug treatment of relapsed disease is directed by the platinum-free interval: relapsed platinum-sensitive disease is usually re-treated with platinum-based therapy and platinum-resistant disease challenged with non-platinum drugs. However, the side-effects of chemotherapy agents may be severe and optimal treatment regimens are unclear. Pegylated liposomal doxorubicin (PLD), which contains a cytotoxic drug called doxorubicin hydrochloride is one of several treatment modalities that may be considered for single-agent treatment of relapsed EOC, or used in combination with other drugs. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 25% |
India | 1 | 13% |
Unknown | 5 | 63% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 75% |
Science communicators (journalists, bloggers, editors) | 1 | 13% |
Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 1% |
Spain | 1 | <1% |
Ecuador | 1 | <1% |
Canada | 1 | <1% |
Unknown | 192 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 29 | 15% |
Student > Bachelor | 22 | 11% |
Researcher | 21 | 11% |
Other | 19 | 10% |
Student > Ph. D. Student | 18 | 9% |
Other | 28 | 14% |
Unknown | 60 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 81 | 41% |
Nursing and Health Professions | 13 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
Agricultural and Biological Sciences | 6 | 3% |
Biochemistry, Genetics and Molecular Biology | 5 | 3% |
Other | 22 | 11% |
Unknown | 63 | 32% |